PURPOSE: Immunohistochemical staining of radical prostatectomy specimens for p53 and bcl-2 proteins has been shown to correlate with prostate specific antigen (PSA) recurrence in a series of patients at our institution. We analyzed the relationship between staining of diagnostic prostate needle biopsies for p53 and bcl-2, and PSA recurrence. MATERIALS AND METHODS: From 1986 to 1993, 335 radical prostatectomies were performed at our hospital. Of the prostatectomy specimens 199 had been evaluated for p53 and bcl-2 proteins in a prior series. Of 139 patients with biopsy material available for analysis 129 had enough for evaluation of 1 or both markers. Prospectively obtained clinical followup data were available, with a mean followup of 6 years. Commercially available antibodies were used for immunohistochemical staining. RESULTS: The overall PSA recurrence rate was 37.6% for 199 radical prostatectomy cases and 37.9% for 129 with biopsy immunohistochemical staining. Staining of prostatectomies correlated well with PSA recurrence for p53 (p = 0.004) and bcl-2 (p = 0.001). However, biopsy staining did not correlate with prostatectomy staining or PSA recurrence for either marker. CONCLUSIONS: The p53 and bcl-2 biomarkers appear to be important to predict recurrence of prostate cancer when prostatectomy specimens are analyzed but this usefulness is not apparent with immunohistochemical staining of prostate biopsies. This difference may reflect sampling error and/or the heterogeneous nature of prostate cancers, and deserves further study.
PURPOSE: Immunohistochemical staining of radical prostatectomy specimens for p53 and bcl-2 proteins has been shown to correlate with prostate specific antigen (PSA) recurrence in a series of patients at our institution. We analyzed the relationship between staining of diagnostic prostate needle biopsies for p53 and bcl-2, and PSA recurrence. MATERIALS AND METHODS: From 1986 to 1993, 335 radical prostatectomies were performed at our hospital. Of the prostatectomy specimens 199 had been evaluated for p53 and bcl-2 proteins in a prior series. Of 139 patients with biopsy material available for analysis 129 had enough for evaluation of 1 or both markers. Prospectively obtained clinical followup data were available, with a mean followup of 6 years. Commercially available antibodies were used for immunohistochemical staining. RESULTS: The overall PSA recurrence rate was 37.6% for 199 radical prostatectomy cases and 37.9% for 129 with biopsy immunohistochemical staining. Staining of prostatectomies correlated well with PSA recurrence for p53 (p = 0.004) and bcl-2 (p = 0.001). However, biopsy staining did not correlate with prostatectomy staining or PSA recurrence for either marker. CONCLUSIONS: The p53 and bcl-2 biomarkers appear to be important to predict recurrence of prostate cancer when prostatectomy specimens are analyzed but this usefulness is not apparent with immunohistochemical staining of prostate biopsies. This difference may reflect sampling error and/or the heterogeneous nature of prostate cancers, and deserves further study.
Authors: J Javid; R Mir; M Mirza; A Imtiyaz; Y Prasant; Z Mariyam; P K Julka; A Mohan; M Lone; P C Ray; A Saxena Journal: Clin Transl Oncol Date: 2014-09-26 Impact factor: 3.405
Authors: C Deliveliotis; A Skolarikos; A Karayannis; V Tzelepis; N Trakas; E Alargof; V Protogerou Journal: World J Urol Date: 2003-07-03 Impact factor: 4.226
Authors: Joseph Nariculam; Alex Freeman; Simon Bott; Phillipa Munson; Noriko Cable; Nicola Brookman-Amissah; Magali Williamson; Roger S Kirby; John Masters; Mark Feneley Journal: Asian J Androl Date: 2008-12-01 Impact factor: 3.285
Authors: Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin Journal: Prostate Date: 2008-12-01 Impact factor: 4.104
Authors: Christopher S Gomez; Pablo Gomez; Judith Knapp; Merce Jorda; Mark S Soloway; Vinata B Lokeshwar Journal: J Urol Date: 2009-08-14 Impact factor: 7.450